Available Technologies
# of Displayed Technologies: 1 / 1
Categories
Inhibition of Purinergic Signaling to Promote Neotissue Formation and Prevent Pathological Remodeling in Tissue Engineered Vascular Conduits, Patches, and Valves.
TS-004524 — In engineered cardiovascular tissues, inhibiting purinergic signaling will promote high-quality neo tissue formation and prevent pathological remodeling. Inhibiting the P2Y12 receptor sustains a multitude of other necessary functions but prevents a detrimental excess.
To promote high quality neo tissue formation and inhibit pathological remodeling within engineered cardiovascular tissues, purinergic signaling must be inhibited. The P2Y12 receptor inhibitor called prasugrel, or Effient®, reduces the rate of thrombotic cardiovascular (CV) events (including sten…
- College:
- Inventors: Breuer, Christopher; Reinhardt, James; Turner, Mackenzie
- Licensing Officer: Murrah, Kyle
